Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
08 Agosto 2023 - 5:30PM
Business Wire
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression and other central nervous system
(CNS) disorders, today announced it will host a conference call and
webcast on Thursday, August 10, 2023, at 1:30 p.m. Pacific Time
(4:30 p.m. Eastern Time) to provide a corporate update and report
results for its fiscal year 2024 first quarter ended June 30,
2023.
Event: Vistagen Fiscal Year 2024 First Quarter Corporate
Update Conference Call Date: Thursday, August 10, 2023
Time: 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) US
Dial-in (Toll-free): 1-800-954-1051 TOLL/International
Dial-in: 1-212-231-2924 Conference ID: 22027732
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1627439&tp_key=9f0f4cb009
An audio webcast of the conference call will also be available
via the link provided above. Participants should access this
webcast site 10 minutes before the start of the call. In addition,
a telephone playback of the call will be available after
approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time) on
Thursday, August 10, 2023. To listen to the replay, call toll-free
1-844-512-2921 within the United States or 1-412-317-6671 when
calling internationally (toll). Please use the replay access ID
number: 22027732.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. Vistagen is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those currently available for the treatment
of anxiety, depression and multiple CNS disorders. Vistagen’s
pipeline includes six clinical-stage product candidates, including
fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an
investigational neuroactive nasal spray belonging to a new class of
drugs known as pherines, as well as AV-101, which is an oral
prodrug antagonist of the N-methyl-D-aspartate receptor. Pherine
nasal sprays are administered at low microgram dose and designed
with a novel proposed mechanism of action that activates
chemosensory neurons in the nasal cavity and can beneficially
impact key neural circuits in the brain without systemic uptake or
direct activity on neurons in the brain. Vistagen is passionate
about transforming mental health care and redefining what is
possible in the treatment of anxiety, depression and several other
CNS disorders. Connect at www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230808331013/en/
Investors Mark A. McPartland Senior Vice President,
Investor Relations (650) 577-3606 markmcp@vistagen.com
Media Nate Hitchings SKDK nhitchings@skdknick.com
Vistagen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024